• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Insomnia in Menopause: How do Treatments Compare?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Self-reported sleep problems are common especially during the menopausal transition
  • Guthrie et al. (Sleep, 2018) combined data from multiple studies to describe the efficacy of interventions on severe insomnia symptoms in women with menopause associated vasomotor symptoms (VMS)

METHODS:

  • Pooling of data from 4 MsFLASH RCTs (Menopausal Strategies: Finding Lasting Answers to Symptoms and Health)
  • Common eligibility criteria
    • 40–62 years
    • In the menopause transition, defined as amenorrhea ≥ 60 days in the past year OR postmenopausal, defined as ≥12 months since last menstrual period or bi-lateral oophorectomy) OR had a hysterectomy with one or both ovaries remaining and FSH >20 mIU/mL and estradiol ≤50 pg/mL
    • In good health based on history, physical exam and basic lab tests
    • Adjustments made for differences between studies
  • Analyzed pooled individual-level data from 546 peri- and postmenopausal women with Insomnia Severity Index (ISI) ≥ 12, and ≥14 bothersome VMS/week
    • ISI assesses difficulty falling asleep | difficulty staying asleep |problems with early awakening, satisfaction with current sleep pattern | interference of sleep problem with daily functioning | noticeability of impairment attributed to the sleep problem | degree of distress caused by the sleep problem
      • Each item scored from 0-4
  • Interventions included the following
    • escitalopram 10–20 mg/day
    • yoga
    • aerobic exercise
    • 8 g/day omega-3 fatty acids
    • oral 17-beta-estradiol 0.5-mg/day
    • venlafaxine XR 75-mg/day
    • cognitive behavioral therapy for insomnia (CBT-I), which includes
      • Stimulus control (e.g., not eating too close to bedtime)
      • Sleep hygiene (good sleep environment, e.g., removing distractions)
      • Sleep restriction (controlling time in bed and restoring the ‘bed-sleep’ connection rather than frustration of insomnia)
      • Relaxation training
      • Cognitive therapy (targeted sleep education)
  • Outcome measures included ISI and Pittsburgh Sleep Quality Index (PSQI) over 8–12 weeks of treatment

RESULTS:

ISI

  • CBT-I produced the greatest reduction from baseline relative to control at −5.2 points (95% CI −7.0 to −3.4)
  • Effects similar for exercise at −2.1 and venlafaxine at −2.3 points
  • Small decreases seen with escitalopram, yoga, and estradiol

PSQI

  • The largest reduction from baseline was with CBT-I at −2.7 points (−3.9 to −1.5)
  • Decreases were significant for escitalopram, exercise, yoga, estradiol, and venlafaxine
  • Omega-3 supplements did not improve insomnia symptoms

CONCLUSION:

  • Cognitive behavioral therapy for insomnia was the most effective treatment for menopause associated insomnia, followed by exercise and venlafaxine
  • ACP recommends CBT-I as the initial treatment for chronic insomnia

Learn More – Primary Sources:

Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

North American Menopause Society: Hormone Therapy Statement
Genitourinary Syndrome of Menopause: New Name, Old Problem

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site